Technology
Explore technologies transforming drug discovery and development, including artificial intelligence, automation, genomics, bioinformatics, imaging, robotics, advanced laboratory platforms and computational tools that accelerate target identification, therapeutic innovation and translational research.
Webinars and whitepapers
- Previous
- Next
Technology
ArticleFaster, scalable biologics stability testing without sacrificing data quality
Stability problems can derail promising biologics late in development. Bringing high-throughput testing earlier into discovery could help researchers identify risks before they become costly failures.
InterviewA sceptical guide to AI agents in drug discovery
AI agents promise to transform drug discovery, but where do they really add value? Dr Eric Ma examines search, model choice, vendor lock-in and why scientific expertise matters more than ever.
ArticleDrug discovery in Q3 2026 – what changed and why it matters
Agentic AI, ultralarge virtual screening, molecular glues and human-relevant models were among the key developments in early drug discovery during Q3 2026. Drug Target Review examines what changed, why it matters and what to watch heading into Q4.
ArticleAI agents vs scientists: what should we automate in drug discovery?
AI agents can search, analyse and plan across drug discovery workflows, but where should scientists hand over control? We examine what to automate, what to check and where human judgement matters most.
Join now
Unlock exclusive industry insights
- Bookmark articles and resources to access anytime
- Enjoy free access to industry leading resources, webinars and insights
- Stay informed with the latest news and breakthroughs
- Receive updates and recommendations tailored to your research interests
ArticleHow disease exposes hidden epitopes that AI models may miss
A protein can look very different in disease without a single change to its sequence. Measuring these structural changes could reveal drug targets invisible to genomic and expression data alone.
ArticleHow protective gene variants are revealing new drug targets
Finding the right drug target remains one of discovery’s biggest challenges. Human genetics is helping researchers strengthen the evidence before committing years of research and investment.
ArticleWhy AI struggles with new drug targets – and how physics could help
Virtual screening can assess billions of compounds, but performance can fall on unfamiliar targets. Combining AI with molecular physics could help make predictions more reliable.
ArticleTurning CNS biomarkers into better drug development decisions
Why do promising CNS therapies struggle to translate into patients? Three experts explore how biomarkers can track therapeutic effects, improve patient selection and guide development decisions.
ArticleFast-tracking AI-designed binders with cell-free expression and SPR
AI can rapidly generate new protein binders, but wet-lab validation remains a major bottleneck. Combining cell-free protein synthesis with surface plasmon resonance (SPR) enables AI-designed antibody binders to be screened directly from crude extracts, bypassing lengthy cell culture and purification steps.
ArticleSample collection: the overlooked key to genomic study success
As genomic studies become larger and more diverse, sample collection can make or break their success. Discover why collection strategy matters for recruitment, scale and data quality.
ArticleWhy more ribosomes can mean less protein in mRNA therapeutics
What happens when the cellular machinery making therapeutic proteins slows down? New research in Nature shows why translation speed could matter for the design of mRNA medicines.
ArticleWhy depression needs a different drug discovery strategy
What if depression is not one disease, but many biologically distinct conditions? A major research programme is investigating what this could mean for biomarkers, drug targets and treatment.
ArticleSix assay requirements every researcher using NAMs should know
As NAMs become more widely used in drug discovery, assays must meet the demands of more complex models. Discover six requirements for reliable, reproducible and biologically meaningful data.
ReportBuilding biomarkers that drug developers can rely on
Discover how integrated technologies, multiomic approaches and AI are helping researchers translate complex biological signals into actionable tools for drug development and patient care.
ArticleHow rare genetic variants could uncover new drug targets
What if extreme levels of common traits have a different genetic basis? New research suggests rare, large-effect variants could help explain the extremes and identify potential drug targets.
ArticleHow AI-driven systems biology will reset the starting line for drug development
AI is making drug discovery faster, but can it make it more successful? Discover why combining AI with systems biology could help researchers tackle the biological complexity behind drug failure.
Article600+ patient-derived cancer models expand the search for drug targets
Hundreds of new patient-derived cancer models could strengthen target validation, identify cancer vulnerabilities and provide more representative systems for preclinical drug discovery.
ArticleWhy intracellular targets remain a major drug discovery challenge – and how they’re becoming druggable
Many biologically important intracellular targets remain difficult to drug. Dr Rab Prinjha examines how screening within living cells could help tackle them.
ArticleFibroblast barrier linked to immunotherapy resistance in colorectal cancer
Why do some colorectal cancers resist immunotherapy? Analysis of patient tumour samples has identified a population of fibroblasts that could help explain treatment resistance.